Wall Street Club Release: CODX Spike Nearly 26% on 53x Avg Volume Following News of Presentation with LGC, Biosearch
NEW YORK CITY, NEW YORK / ACCESSWIRE / January 15, 2019 / Share prices ofCo-Diagnostics, Inc., (NASDAQ: CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, hit highs of $1.54 on Monday, January 14, nearly 26% higher than the previous close and on a healthy trading volume just shy of 1.13M – over 53 times the daily average. The movement comes after news of Co-Diagnostics’ participation and presentation as a guest of LGC, Biosearch Technologies (LGC) at the 27th International Plant and Genome conference (PAG XXVII), held this week in San Diego.
CODX shares followed suit as the Nasdaq Composite (IXIC) trended downward to end 2018. Nasdaq’s recovery has already begun, so time will tell whether this positive movement is an indication that CODX is gearing up for a recovery of its own, building on the momentum of the Company’s participation in PAG XXVII and their 2018 accomplishments as discussed by Company CEO Dwight Egan in a virtual investor conference in December. CODX shares ultimately settled at $1.29 on January 14, up over 14% on the day.
Following the signing of a license agreement in October 2018, the flexibility and scalability of Co-Diagnostics’ patented CoPrimer™ technology have been available to customers of LGC, who is owned by funds affiliated with KKR, and whose 2,300 employees operate out of 19 countries worldwide with a strategy to develop highly innovative tools in the polymerase chain reaction (PCR) diagnostics space. LGC is described as an international leader in the extended life sciences sector and in the design, development, and manufacture of sophisticated, custom oligonucleotide-based tools and associated reagents for applied markets.
With over 3,000 leading genetic scientists and researchers from academic and enterprise organizations expected to attend PAG XXVII, Co-Diagnostics believes that in addition to LGC’s global customer base, the presentation will also generate increased awareness of the Company’s groundbreaking technological advances in multiplex PCR and SNP genotyping among the agrigenomics industry worldwide.
Mr. Egan, who in October anticipated that the CoPrimer license agreement with LGC would be the first such agreement of many, wasquoted as being “honored to present with LGC at the PAG conference, arguably the best global forum for the CoPrimer platform to gain international recognition for its applications in the ag-bio industry,” and as saying that he believed “LGC customers will greatly benefit from the scalability and cost-savings advantages of adopting CoPrimers in their businesses.”
About The Wall Street Club:
The Wall Street Club (WSC) is a financial digital media company whose focus is to provide readers with news and content on the latest trends and happenings in the financial industry. WSC writes about stocks in both free and paid content. WSC accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished ornon-public information.
The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from aninvestor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the Wall Street Club may at times hold a position in the company covered within the article. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, andexpansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differmaterially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. The Wall Street Club is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.
The Wall Street Club
SOURCE: Co-Diagnostics, Inc.